Clinical Trial Update: A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 [Phase 2]

View source ↗

Summary

Phase 2a study evaluating safety, tolerability, and levodopa pharmacokinetics in Parkinson's disease patients treated with ND0612; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 (ND0612)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED